Association of CYP2C9*2 With Bosentan‐Induced Liver Injury

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical pharmacology and therapy

• Publication date

  2013-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/clpt.2013.143PMID 23863877PMCID PMC3834031
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis

  2013cited by this paper
• Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.

  2013cited by this paper
• Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

  2012cited by this paper
• Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys.

  2012cited by this paper
• FUNCTIONAL CHARACTERIZATION OF ABCC2 PROMOTER POLYMORPHISMS AND ALLELE SPECIFIC EXPRESSION

  2012cited by this paper
• The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.

  2012cited by this paper
• The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.

  2012cited by this paper
• Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

  2011cited by this paper
• Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants

  2011cited by this paper
• Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CA genotype in female patients in North India

  2011cited by this paper
• Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy.

  2011cited by this paper
• Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity

  2011cited by this paper
• CYP2C9*1B Promoter Polymorphisms, in Linkage with CYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose

  2010cited by this paper
• Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

  2010cited by this paper
• Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.

  2010cited by this paper
• Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability

  2010cited by this paper
• Expert Consensus Document 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents

  2010cited by this paper
• Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches.

  2009cited by this paper
• A genome-wide association study of acenocoumarol maintenance dosage.

  2009cited by this paper
• A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

  2008cited by this paper
• Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol

  2008cited by this paper
• Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy

  2008cited by this paper
• Results of European post-marketing surveillance of bosentan in pulmonary hypertension

  2007cited by this paper
• Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

  2007cited by this paper
• Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

  2007cited by this paper
• Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases

  2007cited by this paper
• Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance–associated protein 2

  2007cited by this paper
• The effectiveness of two occupational health intervention programmes in reducing sickness absence among employees at risk. Two randomised controlled trials

  2007cited by this paper
• The bile salt export pump

  2007cited by this paper
• Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil

  2007cited by this paper
• A USA-based registry for pulmonary arterial hypertension: 1982–2006

  2007cited by this paper
• Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury

  2007cited by this paper
• MRP2 haplotypes confer differential susceptibility to toxic liver injury

  2007cited by this paper
• Clinical Consequences of Cytochrome P450 2C9 Polymorphisms

  2005cited by this paper
• Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

  2004cited by this paper
• Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2

  2004cited by this paper
• Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.

  2004cited by this paper
• Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans

  2003cited by this paper
• BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION

  2002cited by this paper
• Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

  2002cited by this paper
• Bosentan therapy for pulmonary arterial hypertension.

  2002cited by this paper
• Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan.

  2002cited by this paper
• Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

  2002cited by this paper
• The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.

  2001cited by this paper
• Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

  2001cited by this paper
• In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.

  2001cited by this paper
• The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions

  2001cited by this paper
• [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].

  2001cited by this paper
• Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.

  1999cited by this paper
• Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

  1995cited by this paper
• Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

  1993cited by this paper
• Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.

  1993cited by this paper
• An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

  1992cited by this paper
• Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

  1991cited by this paper

• Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity

  2025cites this paper
• Predicting Systemic and Liver Bosentan Exposure Using Physiologically‐Based Pharmacokinetic Modeling

  2025cites this paper
• Drug metabolizing enzymes and transporters, and their roles for the development of drug-induced liver injury

  2025cites this paper
• Idiosyncratic DILI and RUCAM under One Hat: The Global View

  2023cites this paper
• Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives

  2023cites this paper
• Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis

  2022cites this paper
• The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study

  2022cites this paper
• Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report

  2022cites this paper
• Transporter, Drug Metabolism, and Drug‐Induced Liver Injury in Marketed Drugs

  2021cites this paper
• Liver Organoids: Updates on Disease Modeling and Biomedical Applications

  2021cites this paper
• Genetic Polymorphism of Drug‐Metabolizing Enzymes and Drug Transporters in Drug Toxicity

  2021cites this paper
• Human Three-Dimensional Hepatic Models: Cell Type Variety and Corresponding Applications

  2021cites this paper
• Bosentan Alters Endo- and Exogenous Bile Salt Disposition in Sandwich-Cultured Human Hepatocytes

  2021cites this paper
• A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension

  2021cites this paper
• Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats

  2020cites this paper
• Oral drugs used to treat persistent pulmonary hypertension of the newborn

  2020cites this paper
• High-Fidelity Drug Induced Liver Injury Screen Using Human PSC-derived Organoids.

  2020cites this paper
• Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis

  2020cites this paper
• Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.

  2020cites this paper
• Pluripotent Stem Cell-Derived Human Liver Organoids Enter the Realm of High-Throughput Drug Screening.

  2020cites this paper
• Phase I study of PF‐04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasis

  2019cites this paper
• A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.

  2019cites this paper
• Biomarkers of drug-induced liver injury.

  2019cites this paper
• The evolution of ideas about medicinal liver damage

  2019cites this paper
• Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent.

  2018cites this paper
• Drug-Induced Liver Toxicity

  2018cites this paper
• Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation

  2018cites this paper
• Principles of precision medicine and its application in toxicology.

  2018cites this paper
• Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI)

  2018cites this paper
• Causality Assessment Methods in Drug-Induced Liver Injury

  2018cites this paper
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†

  2017cites this paper
• Drug-induced liver injury: Do we know everything?

  2017cites this paper
• Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations

  2017influential citation
• Drug‐induced Hepatotoxicity

  2017cites this paper
• Metabolism study and biological evaluation of bosentan derivatives.

  2016cites this paper
• Assessment of Association Cytochrome Р450 Gene Polymorphism with Pathogenesis and Course of HСV in Uzbek Population.

  2016cites this paper
• Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes

  2016influential citation
• Effect of Bosentan and Losartan on Oxidative Stress and Cortisol level in Endothelin-1 and Angiotensin II Treated Rats

  2016cites this paper
• 3. Metabolism: Principle, Methods, and Applications

  2015cites this paper
• 9. Translational Tools toward Better Drug Therapy in Human Populations

  2015cites this paper
• The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.

  2015cites this paper
• RUCAM in Drug and Herb Induced Liver Injury: The Update

  2015cites this paper
• The Emerging Discipline of Quantitative Systems Pharmacology

  2015cites this paper
• Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension

  2015cites this paper
• Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population

  2014cites this paper
• imultaneous determination of bosentan and glimepiride in human lasma by ultra performance liquid chromatography tandem mass pectrometry and its application to a pharmacokinetic study

  2014cites this paper
• Simultaneous determination of bosentan and glimepiride in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study.

  2014cites this paper
• Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan.

  2014cites this paper
• Genetic Basis of Drug-Induced Liver Injury: Present and Future

  2014cites this paper
• Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury

  2014cites this paper
• Drug-induced liver injury: what was new in 2013?

  2014influential citation
• Studies on the mechanism of flucloxacillin-induced liver injury

  2014cites this paper
• CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers

  2014cites this paper
• Response to “CYP2C9 Polymorphism is Not a Major Determinant of Bosentan Exposure in Healthy Volunteers”

  2014cites this paper
• CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan‐Induced Liver Toxicity

  2014cites this paper
• Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.

  2014cites this paper
• Managing the Risk of Drug‐Induced Liver Injury

  2013cites this paper